“Move Fast and Vape Things” is worth watching

The New York Times just released its new one hour documentary on the origins of Juul, Move Fast and Vape Things. (You can watch a trailer and some clips from the film and link to Hulu, where the full film is available, here.) The film includes interviews with an addicted teen, the two men whoContinue reading ““Move Fast and Vape Things” is worth watching”

FDA denied over 1 million e-cig flavored products but not a single one with menthol

Despite the fact that menthol and mint are wildly popular with kids (and contribute to keeping adults addicted), the FDA Center for Tobacco Products has yet to prohibit the sale of a single menthol e-cigarette flavor. The CTP News sent out today reported: FDA Denies Marketing Applications for Over 1 Million Flavored E-Cigarette ProductsIn August,Continue reading “FDA denied over 1 million e-cig flavored products but not a single one with menthol”

E-cigs have been on the market for 15 years: If they were really reducing harm it would be obvious by now

Ever since e-cigarettes first came on the market in 2006 the argument has been that it will take time for their health benefits to be manifest. This view was restated again last month in an FDA press release that stated, “Companies who want to continue to market their flavored ENDS products must have robust andContinue reading “E-cigs have been on the market for 15 years: If they were really reducing harm it would be obvious by now”

British American Tobacco (BAT) Conducted Extensive and Potentially Illegal Activity To Undermine Health Policy, Sabotage Competitors And Secure Profits In Africa

Researchers led by Anna Gilmore at the University of Bath just published three jaw-dropping reports on British American Tobacco’s (BAT) allegedly illegal activities in Africa to undermine competitors through surveillance, bribes and dirty tricks. (They also contributed 273 new documents to the UCSF Truth Tobacco Industry Documents Library they used in this work, so theContinue reading “British American Tobacco (BAT) Conducted Extensive and Potentially Illegal Activity To Undermine Health Policy, Sabotage Competitors And Secure Profits In Africa”

PMPSA’s Population Health Impact Model for IQOS underestimates the health impact of IQOS, does not adequately address new published research and information on population health impacts, and does not demonstrate benefits to individual or population health, so FDA should not issue an exposure modification MRTP order for IQOS 3

My colleagues and I at the UCSF TCORS submitted this public comment to the FDA. The Regulations.gov tracking number is kta-koyn-mf7k. A PDF is available here. PMPSA’s Population Health Impact Model for IQOS underestimates the health impact of IQOS, does not adequately address new published research and information on population health impacts, and does notContinue reading “PMPSA’s Population Health Impact Model for IQOS underestimates the health impact of IQOS, does not adequately address new published research and information on population health impacts, and does not demonstrate benefits to individual or population health, so FDA should not issue an exposure modification MRTP order for IQOS 3”

PMPSA’s supplemental modified risk tobacco product application for IQOS 3 does not support the conclusion that IQOS will not harm vascular endothelial function and does not address new published research, so FDA should not issue an exposure modification MRTP order for IQOS 3 support the conclusion that IQOS will not harm vascular endothelial function and does not address new published research, so FDA should not issue an exposure modification MRTP order for IQOS 3

My colleagues and I at the UCSF TCORS just submitted this public comment to the FDA. The tracking number on Regulations.gov is kta-aq6w-3tph. A PDF is available here. PMPSA’s supplemental modified risk tobacco product application for IQOS 3 does not support the conclusion that IQOS will not harm vascular endothelial function and does not addressContinue reading “PMPSA’s supplemental modified risk tobacco product application for IQOS 3 does not support the conclusion that IQOS will not harm vascular endothelial function and does not address new published research, so FDA should not issue an exposure modification MRTP order for IQOS 3 support the conclusion that IQOS will not harm vascular endothelial function and does not address new published research, so FDA should not issue an exposure modification MRTP order for IQOS 3”

FDA can and should prioritize youth over Juul and other e-cigs sales while it ponders the long term

After years of delays and deadline extensions that allowed thousands of e-cigarettes to remain on the market without any FDA premarket review and millions of kids to become nicotine addicts, health groups successfully sued FDA to force action. As a result, on July 11, 2019 Judge Paul Grimm ordered FDA to require premarket tobacco product applications (PMTAs) forContinue reading “FDA can and should prioritize youth over Juul and other e-cigs sales while it ponders the long term”

Understanding how unhealthy food companies influence advertising restrictions

Advertising is a key vector used to promote unhealthy products, and there is a long history of efforts to ban or restrict advertising as a key element of tobacco control. Advertising restrictions are also starting to be implemented to protect the public from promotions for other unhealthy products, including junk food. In particular, in 2019Continue reading “Understanding how unhealthy food companies influence advertising restrictions”

IQOS emissions create risks of immunosuppression and pulmonary toxicity and the supplemental modified risk tobacco product application for IQOS 3 does not address new published research on these risks, so FDA should not issue an exposure modification MRTP order for IQOS 3

My colleagues and I at the UCSF TCORS submitted this public comment to the FDA. The Regulations.gov tracking number is kt4-u9mw-wc65. A PDF version is available here. IQOS emissions create risks of immunosuppression and pulmonary toxicity and the supplemental modified risk tobacco product application for IQOS 3 does not address new published research on theseContinue reading “IQOS emissions create risks of immunosuppression and pulmonary toxicity and the supplemental modified risk tobacco product application for IQOS 3 does not address new published research on these risks, so FDA should not issue an exposure modification MRTP order for IQOS 3”

President Biden willing to eliminate vaping

At a campaign stop on January 6, 2020, then-candidate Joe Biden said he would prioritize health over business and eliminate vaping if the evidence showed damage to lungs and other bad effects. E-cigs do damage lungs and much more. So the FDA doesn’t have to worry about the President blocking them as Obama and TrumpContinue reading “President Biden willing to eliminate vaping”